Hsbc Holdings PLC Takes Position in Natera, Inc. $NTRA

Hsbc Holdings PLC acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA) during the second quarter, according to its most recent filing with the SEC. The fund acquired 86,750 shares of the medical research company’s stock, valued at approximately $23,551,000. Hsbc Holdings PLC owned 0.06% of Natera as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. EFG International AG bought a new position in Natera in the 2nd quarter worth about $13,263,000. Canada Pension Plan Investment Board bought a new stake in shares of Natera during the second quarter valued at about $33,741,000. Castleark Management LLC bought a new stake in shares of Natera during the second quarter valued at about $755,000. Legal & General Group Plc purchased a new stake in shares of Natera in the second quarter worth about $150,143,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Natera in the second quarter valued at approximately $18,153,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total value of $905,627.80. Following the transaction, the insider owned 129,019 shares of the company’s stock, valued at $34,264,866.02. This represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 295 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $267.99, for a total value of $79,057.05. Following the completion of the transaction, the insider directly owned 183,774 shares in the company, valued at approximately $49,249,594.26. This represents a 0.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 177,955 shares of company stock worth $40,704,193. Corporate insiders own 5.05% of the company’s stock.

Natera Price Performance

Shares of NTRA opened at $338.70 on Friday. The firm’s 50 day simple moving average is $283.17 and its 200 day simple moving average is $232.96. The company has a market capitalization of $48.82 billion, a P/E ratio of -249.04 and a beta of 1.51. Natera, Inc. has a 1-year low of $157.43 and a 1-year high of $343.18.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.74) EPS. On average, equities analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on NTRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. The Goldman Sachs Group started coverage on shares of Natera in a research report on Friday, June 5th. They set a “neutral” rating and a $245.00 price target for the company. Guggenheim upped their price target on shares of Natera from $290.00 to $360.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Piper Sandler increased their price objective on Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Finally, Robert W. Baird set a $348.00 price objective on Natera in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $319.38.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.